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Abstract: Background: Genetic polymorphisms of drug metabolizing enzymes can substantially 
modify the pharmacokinetics of a drug and eventually its efficacy or toxicity; however, inferring a 
patient’s drug metabolizing capacity merely from his or her genotype can lead to false prediction. 
Non-genetic host factors (age, sex, disease states) and environmental factors (nutrition, co-
medication) can transiently alter the enzyme expression and activities resulting in genotype-
phenotype mismatch. Although valproic acid is a well-tolerated anticonvulsant, pediatric patients 
are particularly vulnerable to valproate injury that can be partly attributed to the age-related differ-
ences in metabolic pathways. 
Methods: CYP2C9 mediated oxidation of valproate, which is the minor metabolic pathway in 
adults, appears to become the principal route in children. Genetic and non-genetic variations in 
CYP2C9 activity can result in significant inter- and intra-individual differences in valproate phar-
macokinetics and valproate induced adverse reactions. 
Results: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in 
valproate metabolism in children; furthermore, low CYP2C9 expression in patients with 
CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. Due to pheno-
conversion, the homozygous wild genotype, expected to be translated to CYP2C9 enzyme with 
normal activity, is transiently switched into poor (or extensive) metabolizer phenotype. 
Conclusion: Novel strategy for valproate therapy adjusted to CYP2C9-status (CYP2C9 genotype 
and CYP2C9 expression) is strongly recommended in childhood. The early knowledge of pediatric 
patients’ CYP2C9-status facilitates the optimization of valproate dosing which contributes to the 
avoidance of misdosing induced adverse reactions, such as abnormal blood levels of ammonia and 
alkaline phosphatase, and improves the safety of children’s anticonvulsant therapy. 
Keywords: Valproic acid, epilepsy, psychiatric disorders, CYP2C9 genotype, CYP2C9 expression, personalized medication, 
pediatric patients. 
1. INTRODUCTION 
 A patient’s drug metabolizing capacity highly influences 
his or her response to a drug; therefore, genetic variations or 
alterations in the expression and activities of drug metaboliz-
ing enzymes can substantially modify the pharmacokinetics 
of a drug and eventually its efficacy or toxicity [1]. The rou-
tine clinical practice generally applies symptom driven drug 
therapy with or without blood concentration guided dosing; 
however, the inter-individual variability in drug metabolism 
calls for personalized medication primarily for drugs with 
narrow therapeutic index [2, 3]. The identification of genetic  
 
 
*Address correspondence to this author at the Institute of Enzymology, 
Research Centre for Natural Sciences, Hungarian Academy of Sciences, 
Budapest, Hungary; Tel: (36 1) 382-6747; E-mail: monostory.katalin@ttk.mta.hu 
and non-genetic factors that can potentially affect the phar-
macokinetics of a particular drug is a prerequisite of tailored 
pharmacotherapy [4, 5]. Although in vitro pharmacokinetic 
and enzyme mapping studies provide useful information 
about the metabolic pathways and the enzymes responsible 
for the biotransformation of a drug, the clinical significance 
of these factors must be verified [6-8]. The first step is to 
identify the major enzyme(s) involved in the biotransforma-
tion of a particular drug at clinically relevant concentration. 
Clinical studies generally focus on the functional impact  
of genetic variations in drug metabolizing enzymes; how-
ever, regulation of enzyme expression and inhibition of en-
zyme function are also of high importance for predicting the 
fate of a drug and the clinical outcome of drug therapy. For 
such an approach, a reliable diagnostic tool is required to 
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elimination. The characterization of patients’ drug metabo-
lizing capacity can facilitate more precise prediction of the 
fate of a drug and can contribute to the improvement of drug 
therapy. 
2. CYTOCHROME P450 (CYP) ENZYMES 
 CYP enzymes, the key players in the metabolism of most 
drugs, convert lipophilic compounds to more polar metabo-
lites which are readily excreted [9]. In humans, 57 functional 
CYP genes have been identified; however, only 10 to 12 en-
zymes belonging to the CYP1, CYP2 and CYP3 enzyme 
families are involved in the metabolism of the majority of 
drugs, whereas others are responsible for endobiotic 
biotransformation (e.g. steroids, prostaglandins, fatty acids, 
retinoic acid) [10, 11]. Although the overlapping substrate 
specificities of the drug metabolizing CYPs could ensure a 
balanced metabolic rate, many drugs display great inter-
individual and intra-individual variations in their pharma-
cokinetics [12]. It can be attributed to several facts: i) many 
drugs are metabolized at therapeutic concentrations only by 
one or two CYP enzymes [13], ii) the expression and activi-
ties of CYP enzymes display substantial, even more than 
100-fold inter-individual variability [14], iii) loss-of-function 
or gain-of-function mutations in CYP genes result in perma-
nent poor or extensive metabolism, whereas non-genetic 
(internal or environmental) factors can modify drug metabo-
lizing capacity, evoking transient poor or extensive metabo-
lism [1, 13, 15]. Plenty of CYP genetic variants have been 
identified, and the clinical relevance for some of them has 
been clearly evidenced [13, 15, 16]. CYP genotype deter-
mines the potential for the expression of functional or non-
functional enzymes; thus, the heritable genetic polymor-
phisms can explain some inter-individual differences in drug 
metabolism. However, non-genetic host factors (age, sex, 
disease states) and environmental factors (nutrition, medica-
tion, smoking, alcohol consumption) can alter the expression 
and activities of CYP enzymes [17]. Due to phenoconver-
sion, homozygous wild genotype, expected to be translated 
to CYP enzyme with normal activity, can be transiently 
switched into poor or extensive metabolizer phenotype [1]. 
Consequently, both the CYP genotype and the current CYP 
expression must be considered for the estimation of a pa-
tient’s drug metabolizing capacity. CYPtestTM, a complex 
diagnostic system has been introduced for the estimation of 
patients’ drug metabolizing capacity by CYP genotyping and 
by CYP expression in leukocytes [14]. Although hepatic 
CYP activities are the best for characterization of a patient’s 
drug metabolizing status, liver biopsies are generally not 
available, whereas peripheral blood is a more easily accessi-
ble sample. First CYP genotyping for loss-of-function or 
gain-of-function mutations is carried out by hydrolysis single 
nucleotide polymorphism assay (TaqMan assay) and allelic 
discrimination, then CYP expression is quantified in periph-
eral leukocytes by quantitative real-time PCR analysis. CYP 
mRNA levels in leukocytes isolated from peripheral blood 
were demonstrated to provide information about hepatic 
CYP activities in those subjects who do not carry polymor-
phic alleles. The knowledge of a patient’s CYP-status may 
facilitate tailoring of drug therapy by the choice of the ap-
propriate drug and dosage. 
3. POLYMORPHIC METABOLISM OF VALPROIC 
ACID 
 Valproic acid is one of the first choices of antiepileptic 
therapy, and is successfully applied for treatment of both 
generalized and partial seizures [18]. Furthermore, it is effec-
tively used in the adjuvant therapy of psychiatric disorders, 
such as schizophrenia and bipolar disorder [19-21]. It is 
well-tolerated by most of the patients, and serious side ef-
fects, including bone marrow suppression, coagulopathy, 
hepatotoxicity, hyperammonemic encephalopathy and bone 
metabolic disorders rarely occur [22-25]. Pediatric patients 
appear to be more vulnerable to valproic acid induced injury 
than adults; the risk of serious adverse reactions is signifi-
cantly increased in children younger than 2 years of age, 
especially who have pre-existing neurologic or other medical 
defects or who are under multiple anticonvulsant therapy 
[25-27]. Although the mechanism of valproic acid induced 
adverse reactions is not clearly understood, the cytotoxicity 
and mitochondrial dysfunction are attributed to the parent 
compound and some of its unsaturated metabolites [28-31]. 
 Valproic acid is a simple, branched short-chain carbox-
ylic acid, which is extensively metabolized in the liver, and 
less than 3% of the administered dose is excreted as un-
changed parent compound. Biotransformation of valproic 
acid results in several hydroxylated, unsaturated and conju-
gated metabolites (Fig. 1) [32]. In adults on monotherapy, 
conjugation with glucuronic acid is the major metabolic 
pathway, and 30-50% of the dose is converted to valproate-
glucuronide. Mitochondrial β-oxidation, forming 2-ene-
valproate and 3-keto-valproate, accounts for approximately 
40% of the dose, whereas the minor metabolic pathway cata-
lysed by CYP enzymes eliminates 10-15% of the dose, pro-
ducing hydroxylated metabolites (3-, 4-, and 5-hydroxy-
valproate metabolites) and 4-ene-valproate [31, 33, 34]. 
CYP2C9 has been demonstrated to be the main catalyst of 
CYP-mediated hydroxylation and desaturation, while 
CYP2A6 and CYP2B6 display minor contribution to val-
proic acid metabolism [34]. In mitochodria, the 4-ene me-
tabolite is further desaturated to 2,4-diene-valproate which is 
conjugated with glutathione [32]. 
 In contrast to the ratio of valproate metabolic routes in 
adults, the CYP-catalysed oxidation can become the princi-
pal pathway in those special cases when glucuronidation or 
mitochondrial β-oxidation pathways are compromised or 
poorly developed, for example, in children. The expression 
of UDP-glucuronyl transferases is known to be developmen-
tally regulated [35, 36]; the enzymes responsible for glucu-
ronidation of valproic acid are poorly expressed in infants, 
and their activities slightly increase, however, they are under 
the adult levels, sometimes 10-15 years of age. Therefore, 
the formation of valproate-glucuronide is poor in pediatric 
patients, primarily in children younger than 2 years of age 
[37]. Furthermore, valproic acid and/or some of its metabo-
lites inhibit mitochondrial β-oxidation [31, 38]. On the other 
hand, CYP expression and activities in children exceed adult 
levels, and decrease to the adult activities by puberty [36, 
39]. Consequently, larger proportion of the administered 
valproic acid dose is metabolized by CYP enzymes in chil-
dren than in adults. Shifting the metabolic pathways in chil-
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dren can account for the age-related differences in the inci-
dence of valproic acid induced adverse reactions. 
 CYP2C9, primarily responsible for hydroxylation and 
4-ene desaturation of valproic acid, is a polymorphic enzyme 
with the highest frequency of CYP2C9*2 and CYP2C9*3 
alleles in Caucasian white populations [15, 40]. The preva-
lence of these two alleles displays inter-ethnic differences. 
CYP2C9*2 is almost absent in Asian and African popula-
tions, whereas it is present in 10-19% of Europeans. The 
frequency of CYP2C9*3 is 3-6% in Asians, 1-5% in Africans 
and 6-9% in Europeans [15, 41, 42]. The CYP2C9*2 and 
CYP2C9*3 allelic variants result in substantial decrease in 
CYP2C9 enzyme activity due to reduced interaction with 
NADPH-CYP-reductase or with CYP2C9 substrate, respec-
tively [43-45]. These loss-of-function mutations of CYP2C9 
have been demonstrated to be less active in valproate me-
tabolism than the wild type CYP2C9*1 allele [46]. 
CYP2C9*2 and CYP2C9*3 alleles thus lead to genetically 
determined poor metabolism of valproic acid; however, the 
poor metabolizer phenotype can transiently occur in patients 
carrying wild CYP2C9 genotype (CYP2C9*1/*1). Non-
genetic factors, such as age, co-morbidities, nutrition or co-
medication, can modulate a patient’s valproate metabolizing 
capacity by reducing (or increasing) CYP2C9 expression, 
resulting in weaker (or more extensive) metabolizer pheno-
type. This genotype-phenotype mismatch may give rise to 
more poor metabolizers than it would be predicted from 
CYP2C9 genotype [1]. 
4. CYP2C9-STATUS GUIDED VALPROIC ACID 
THERAPY 
4.1. Valproate Blood Concentration as a Function of 
CYP2C9 
 Predicting a patient’s drug metabolizing phenotype is 
highly complex, requiring the basic knowledge of his or her 
genotypes of drug metabolizing enzyme(s). However, infer-
ring the valproate metabolizing phenotype from CYP2C9 
genotype may lead false prediction because non-genetic fac-
tors can significantly alter drug metabolizing phenotype. In 
patients carrying the loss-of-function CYP2C9*3 allele, Tan 
et al. [47] have demonstrated somewhat higher valproate 
plasma concentrations normalized by the dose and the 
 
Fig. (1). Metabolic pathways of valproic acid. In adults, the majority of valproate dose is eliminated via glucuronidation and mitochondrial 
β-oxidation pathways, and about 15-20% of the dose is metabolized by CYP enzymes. In contrast, valproate metabolism is shifted towards 
CYP-dependent route in children. Abbreviations: UGT: UDP-glucuronyl transferase, GSH: glutathion. 
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bodyweight than in those with two wild type alleles (3.9±0.4 
(µg/ml)/(mg dose/kg bw) vs 3.4±0.4 (µg/ml)/(mg dose/kg 
bw) in patients carrying CYP2C9*1/*3 and CYP2C9*1/*1, 
respectively). The CYP2C9*3 evoked slight increase in val-
proate levels may be attributed to the facts that Tan et al. 
[47] took neither the CYP2C9 expression nor the age-related 
differences in valproic acid metabolism into account. 
CYP2C9*1/*1 carriers are basically assumed to have func-
tional CYP2C9 enzyme and therefore to be extensive me-
tabolizers; however, CYP2C9 genotype can be converted to a 
drug metabolizing phenotype different from that would be 
predicted from the genotype. We have reported that pediatric 
patients with CYP2C9*1/*1 genotype expressing CYP2C9 at 
low level displayed significantly higher valproate concentra-
tions (5.13±1.2 (µg/ml)/(mg dose/kg bw)) than normal 
CYP2C9 expressers (2.12±0.5 (µg/ml)/(mg dose/kg bw), 
P<0.0001) [48]. While, no statistically significant differ-
ences in valproic acid concentrations were found between 
the patients with heterozygous genotypes carrying any of the 
polymorphic CYP2C9 alleles (4.33-5.54±1.2 (µg/ml)/(mg 
dose/kg bw)) and those low CYP2C9 expressers with two 
functional alleles (CYP2C9*1/*1). Consistently, valproic 
acid concentration in children with homozygous wild 
CYP2C9 genotype was influenced by CYP2C9 expression, 
which is considered to be a further evidence for phenocon-
version of CYP2C9*1/*1. 
 Phenoconversion of CYP2C9*1/*1 genotype can be the 
consequence of various factors, such as disease, hormonal 
status, nutrition or co-medication. Multi-drug therapy with 
valproic acid and antiepileptic drugs known to be CYP2C9 
inducers is expected to increase CYP2C9 expression that 
eventually leads to enhanced valproate clearance. The con-
comitant treatment of patients with valproate and phenytoin, 
phenobarbital or carbamazepine has been reported to in-
crease valproate metabolism comparing to the patients on 
valproate monotherapy [49, 50]. Due to the CYP2C9 inducer 
co-administration, the formation of the hepatotoxic 4-ene-
valproate was observed to be elevated in patients [50, 51], 
which can explain the higher risk of hepatotoxicity in those 
 
Fig. (2). Impact of epilepsy and age on CYP2C9 function. Epileptic seizures negatively influence CYP2C9 expression in patients (A) 
comparing to healthy subjects (B). CYP2C9 mRNA levels were determined in leukocytes that can reflect the hepatic CYP2C9 activity. More 
than half of the pediatric patients with epilepsy (44/76) expressed CYP2C9 at low level, whereas the ratio of CYP2C9 low expressers in 
healthy subjects was less than one fifth (15/113). Association between steady-state serum concentrations of valproate and CYP2C9-status 
was demonstrated in children (N=76) (C), but not in adults (N=47) (D). The serum concentrations normalized by the dose and the body-
weight were determined at least four weeks after the beginning of valproate therapy. Solid line means the median of the groups, while * 
means the significant difference (P<0.01). Abbreviations: mut: loss-of-function CYP2C9 allele (CYP2C9*2 or CYP2C9*3), Low: low 
CYP2C9 expressers, Normal: normal CYP2C9 expressers. 
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subjects on polytherapy with CYP2C9 inducers [25, 52]. In 
our recent study involving pediatric patients (<15 years) with 
epilepsy, the ratio of low CYP2C9 expressers was unusually 
high (57.9%), approximately 4-fold higher than in healthy 
adults (13.3%) (Fig. 2A and 2B). The substantial alteration 
in CYP2C9 expression was not attributed to co-medication, 
since no drug therapy was applied at the time of blood sam-
pling. It was rather considered to be the consequence of 
some suppressive factors released during epileptic seizure. In 
the anamnesis of low CYP2C9 expresser children, the preva-
lence of seizures 72 hr before CYPtesting was significantly 
higher than in normal or high expressers (24/44 vs 3/32, 
P<0.0001). In epileptic patients, substantial increase of pro-
inflammatory cytokine release has been observed following 
seizures [53, 54], and the down-regulation of CYP expres-
sion is proposed for the mechanism of cytokine action [55]. 
The down-regulation of CYP2C9 mediated by the pro-
inflammatory IL-6 and IL-1β is the consequence of the re-
pression of pregnane X receptor and constitutive androstane 
receptor [56, 57]. These nuclear receptors transcriptionally 
regulate the expression of several drug metabolizing en-
zymes, including CYP2C9 [58-61]. 
 Age-related changes in valproate pharmacokinetics can 
be explained by distinct priority of metabolic pathways in 
children and adults [37, 62]. The glucuronidation and mito-
chondrial β-oxidation of valproic acid as the major metabolic 
routes in adults appear to be shifted towards CYP2C9 de-
pendent metabolism in children. A significant association 
between CYP2C9-status (determined by CYP2C9 genotype 
and CYP2C9 expression) and valproate serum concentra-
tions has been demonstrated in pediatric patients [48]. In our 
recent follow-up study with adult patients (>18 years), no 
association was observed between valproate pharmacokinetics 
and patients’ CYP2C9-status (Fig. 2C and D). The different 
priority of CYP2C9-dependent and CYP2C9-independent 
metabolism in pediatric and adult patients may contribute to 
the age-related differences in the incidence of valproate in-
duced adverse reactions. Therefore, the identification of the 
genetic and non-genetic factors, influencing valproate me-
tabolizing capacity, can facilitate the optimization of val-
proate therapy. 
4.2. CYP2C9-status Guided Valproic Acid Therapy in 
Children 
 Valproic acid is a drug with narrow therapeutic range, 
and the plasma concentration for optimal therapeutic effect is 
between 40 and 100 µg/ml. In symptom driven antiepileptic 
therapy, low dosages (daily dose of 10-15 mg/kg body-
weight) are initiated, and the target doses are subsequently 
titrated until the optimal clinical response is achieved [23, 
27]. Therapeutic monitoring of valproate is advised; assaying 
valproate plasma concentrations is recommended four weeks 
after the beginning of valproate therapy and later if drug-
interactions, lack of therapeutic effect or overdose-related 
adverse effects are suspected. 
 The novel findings that the steady-state valproate concen-
trations in pediatric patients are in strong association with 
the patients’ CYP2C9-status determined by the genetic vari-
ability of CYP2C9 and by CYP2C9 expression, provided the 
basic tool for personalized antiepileptic therapy [48]. CYP2C9-
status guided valproic acid therapy can be recommended for 
children with at least one or two wild type CYP2C9 alleles 
(CYP2C9*1/*1, CYP2C9*1/*2 or CYP2C9*1/*3) (Fig. 3). 
Normal dose can be applied for the normal CYP2C9 ex-
pressers carrying CYP2C9*1/*1; reduced dose is proposed 
for the children with heterozygous genotypes (CYP2C9*1/*2 
or CYP2C9*1/*3) or for low CYP2C9 expressers, whereas 
the dose of valproic acid is suggested to be increased in high 
expresser patients with CYP2C9*1/*1 genotype. For children 
with two loss-of-function CYP2C9 alleles (CYP2C9*2/*2, 
CYP2C9*3/*3 or CYP2C9*2/*3), an alternative antiepileptic 
(non-valproate) therapy is recommended because of the po-
tential for poor valproate metabolism [63]. In a neonate pa-
tient under valproate therapy, the serious adverse effects, 
such as hyperammonemia, increased serum alkaline phos-
phatase and bone marrow depression, were attributed to re-
duced ability to metabolize valproate [63]. As a consequence 
of two loss-of-function CYP2C9 alleles (CYP2C9*3/*3), the 
exaggerated blood concentration of valproate was likely to 
manifest the toxic symptoms. 
 Special attention has been focused on the age-related 
differences in the incidence of adverse effects associated 
with valproate therapy, which may be attributed to develop-
mental variations in valproate metabolism [30, 37, 62, 64]. 
Valproic acid itself and some of its unsaturated metabolites 
are assumed to be responsible for the side effects, such as 
hematologic disorders or hepatotoxicity [24, 30, 65]. Assign-
ing a prominent role in valproate metabolism to CYP2C9 in 
pediatric patients, the patients’ CYP2C9-status may account 
for the predisposition of some adverse reactions, and both 
loss-of-function mutations in the CYP2C9 gene and low 
CYP2C9 expression can be considered to be the risk factors 
 
Fig. (3). CYP2C9-status guided personalized valproic acid therapy in children. Abbreviations: mut: loss-of-function CYP2C9 allele 
(CYP2C9*2 or CYP2C9*3), Low: low CYP2C9 expressers, Normal: normal CYP2C9 expressers, High: high CYP2C9 expressers. 
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for undesired side effects [48]. The benefit of CYP2C9-
status guided valproate therapy over symptom driven therapy 
has been demonstrated in children [66]. CYP2C9-status 
adapted valproate dosing significantly reduced the ratio of 
patients with blood concentrations out of the therapeutic 
range, and substantially decreased the incidence of hy-
perammonemia and of abnormal serum levels of alkaline 
phosphatase. Hyperammonemia is considered to be associ-
ated with high valproate doses or with exaggerated blood 
concentrations of valproate [66-69]. The increase in blood 
ammonia level, frequently observed in the patients under 
symptom driven valproate therapy (17%), always accompa-
nied with extreme serum levels of alkaline phosphatase and 
with secondary symptoms, such as nausea, somnolence, fa-
tigue, consciousness or behaviour disturbances [66, 70]. 
Therefore, personalized valproic acid therapy adjusted to the 
patients’ CYP2C9-status is strongly recommended, because 
it can improve the safety of antiepileptic therapy in one of 
the most vulnerable patient population [66, 70]. 
CONCLUSION 
 As a consequence of the prominent role of CYP2C9 in 
valproic acid metabolism in pediatric patients, the identifica-
tion of genetic and non-genetic factors that can modify 
CYP2C9 activity is required for the improvement of the 
safety of valproate therapy. The novel strategy of personal-
ized anticonvulsant therapy comprises the following steps: i) 
determination of patient’s CYP2C9-status by revealing the 
allelic variants in CYP2C9 gene and the current CYP2C9 
expression; ii) initiation of non-valproate therapy for patients 
with two loss-of-function CYP2C9 alleles; iii) initiation of 
CYP2C9 adapted valproate dosing for patients with one or 
two wild type alleles (CYP2C9*1); iv) follow-up assaying of 
CYP2C9 expression in patients carrying CYP2C9*1/*1 
genotype, and modification of valproate dosing if necessary. 
Tailored valproate therapy adjusted to the pediatric patients’ 
CYP2C9-status can reduce the risk of exaggerated valproate 
concentrations and misdosing induced serious adverse reac-
tions. 
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